The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Learn more about whether McKesson Corporation or UnitedHealth Group Incorporated is a better investment based on AAII's A+ ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have enlarged exposure to rare disease therapeutics companies as the orphan drugs market sustains robust ...

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.

EVERSANA – which is pharmaphorum's parent company – said that The AI Agency has been set up in collaboration with Google and ...

Switzerland's government was due to hold an extraordinary cabinet meeting on Monday to discuss its response to President ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker ...

Thermo Fisher shows signs of post-COVID recovery, but modest growth, valuation risks, and macro pressures warrant caution.

Local pharma stocks were rocky on Friday after President Donald Trump directed major drugmakers to reduce the cost of their ...

Why pharma companies' "price transparency" reports paint a murky picture of how much Americans spend on prescription drugs.

President Donald Trump's warnings about pharmaceutical tariffs have triggered a wave of manufacturing commitments from major ...

Evidence-based medicine "Boy Wonder" Dr. Vinay Prasad was fired as CBER Director after less than three months on the job.